Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GSK143 dihydrochloride is a highly selective, orally active inhibitor of spleen tyrosine kinase (SYK), exhibiting a pIC 50 value of 7.5. It effectively inhibits phosphorylated Erk (pErk) with a pIC 50 value of 7.1. The compound demonstrates anti-inflammatory properties and hinders the recruitment of immune cells in the intestinal muscularis of mice.
Description | GSK143 dihydrochloride is a highly selective, orally active inhibitor of spleen tyrosine kinase (SYK), exhibiting a pIC 50 value of 7.5. It effectively inhibits phosphorylated Erk (pErk) with a pIC 50 value of 7.1. The compound demonstrates anti-inflammatory properties and hinders the recruitment of immune cells in the intestinal muscularis of mice. |
In vitro | GSK143 dihydrochloride (compound 20) effectively inhibits a range of kinases including ZAP-70 (pIC 50 = 4.7), LCK (pIC 50 = 5.3), LYN (pIC 50 = 5.4), JAK1/2/3 (pIC 50 = 5.8/5.8/5.7), Aurora B (pIC 50 = 4.8), hWB (pIC 50 = 6.6), and hERG (pIC 50 = 4.7). When administered at concentrations ranging from 10 to 10,000 nM every 24 hours over a three-day period, it exhibits an IC 50 of 323 nM in chronic lymphocytic leukaemia (CLL) cells. Additionally, a one-time dose of 1 μM for 30 minutes interrupts early signaling mechanisms, notably SYK phosphorylation and calcium flux. Furthermore, dosages between 0.1 to 10 μM for 30 minutes conditionally lessen cytokine production in bone marrow-derived macrophages. This compound's ability to selectively inhibit these targets, particularly its efficacy at a specific concentration in CLL cells with an IC 50 of 323 nM, underscores its potential for therapeutic applications, demonstrating varied impacts on cellular processes and signaling pathways critical in disease pathogenesis. |
In vivo | GSK143 (0.1-10 mg/kg; orally; 1.5 hours) reduces inflammation and prevents recruitment of immune cells in the intestinal muscularis of 1 mg/kg[3]. GSK143 (3, 10, 30, 100 mg/kg; oral; 1 hour before ovalbumin challenge) reduces the cutaneous reverse passive Arthus reaction in a dose dependent manner by approximately 50% and 70% at 10 mg/kg and 30 mg/kg, respectively[2]. GSK143 (iv of 1 mg/kg; po of 3 mg/kg) has a T 1/2 of 4.2 hours, low clearance (16 mL/min/kg), moderate bioavailability of 30% and a V ss of 4.1 L/kg in rats[1]. Animal Model: Wild type C57NL/BL6 mice, 10-12 weeks old[3]Dosage: 0.1, 1, 3, 10 mg/kg Administration: Orally; 1.5 hours before intestinal manipulation (IM) Result: Reduced inflammation and prevented recruitment of immune cells in the intestinal muscularis. Animal Model: Male CD rats (175-200 g)[1]Dosage: 1 mg/kg of iv; 3 mg/kg of po (Pharmacokinetic Analysis) Administration: IV or PO Result: Had a T 1/2 of 4.2 hours, low clearance (16 mL/min/kg), moderate bioavailability of 30% and a V ss of 4.1 L/kg. |
Molecular Weight | 415.32 |
Formula | C17H24Cl2N6O2 |
CAS No. | 2341796-81-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GSK143 dihydrochloride 2341796-81-2 GSK-143 dihydrochloride GSK143 GSK-143 GSK143 Dihydrochloride GSK 143 Dihydrochloride GSK-143 Dihydrochloride GSK 143 inhibitor inhibit